Soleus Capital Master Fund, L.P. 13D and 13G filings for Jasper Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-02-11 4:00 pm Purchase |
2024-12-31 | 13G | Jasper Therapeutics, Inc. JSPR |
Soleus Capital Master Fund, L.P. | 1,494,420 9.960% |
507,324 (+51.40%) |
Filing |
| 2024-02-02 09:50 am Purchase |
2023-12-31 | 13G | Jasper Therapeutics, Inc. JSPR |
Soleus Capital Master Fund, L.P. | 987,096 8.800% |
987,096 (New Position) |
Filing |